Browsing Category

Top Industry News

7526 posts

BioMarin To Acquire Amicus Therapeutics for $4.8 Bn 
By

By
BioMarin Pharmaceutical, a Dublin, Ireland-based bio/pharmaceutical company, has agreed to acquire Amicus Therapeutics, a Princeton, New Jersey-based bio/pharmaceutical company specializing in rare diseases, for $4.8 billion.  The acquisition will add two new treatments to BioMarin’s existing portfolio of medicines that…

Supplier News: Fujifilm Biosciences, Incog Biopharma, Alcami & More
By

By
The latest from CDMOs, CMOs, and suppliers featuring Fujifilm Biosciences/Chitose, Incog BioPharma Solutions, Alcami, Artis BioSolutions/Syngoi Technologies, Gaelic Laboratories/Athlone Laboratories, Halo Pharma, Sharp Sterile Manufacturing and GBI Manufacturing.   Biologics Manufacturing * Fujifilm Biosciences, Chitose Partner for Cell…

Global Briefs: Novo Nordisk, Sanofi, Lilly, Amgen, BI & More 
By

By
A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Amgen, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, Novo Nordisk, Sanofi, Takeda, Alnylam, Argenx, Arthrosi…

New! Biotech Briefs: Ambros, Rakuten Medical, Soley Therapeutics & More 
By

By
The latest from small and Emerging Pharma companies featuring Ambros Therapeutics, Cytokinetics, Day One Biopharmaceuticals/Mersana Therapeutics, Ikarovec/VectorBuilder, Rakuten Medical, and Soley Therapeutics. For news on the large and mid-sized bio/pharmaceutical…

Lilly To Invest $6 Bn in New US Small-Molecule & Peptide Mfg Facility 
By

By
Eli Lilly and Company has announced plans to invest more than $6 billion in a new small-molecule active pharmaceutical ingredient (API) and peptide manufacturing facility in Huntsville, Alabama. The expansion is part of the company’s multi-year $50-billion investments in US…

Novo Nordisk Completes Acquisition of Akero Therapeutics in $5.2-Bn Deal 
By

By
Novo Nordisk has completed its acquisition of Akero Therapeutics, a South San Franciso, California-based clinical-stage bio/pharma company focused on metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH), in a deal worth…

FDA Names New Acting Director of CDER 
By

By
The US Food and Drug Administration (FDA) has named Tracy Beth Høeg, M.D., Ph.D., currently Senior Advisor for Clinical Sciences in the Office of the Commissioner and the Center for Biologics…

Supplier News: Cytiva, Evonik, Tjoapack & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring AtomVie, Cytiva/Fida Biosystems, Tjoapack, Bora Pharmaceuticals, Quotient Sciences/Intrepid Labs, CABB Chemicals, Quvara Medical, Pace, Evonik, Aptar, Sever Pharma, AmbioPharm and Benunvia/Cannovian.   Chemicals/Chemical API Manufacturing * AtomVie Investing $138 M in New Radiopharma Mfg Facility * CABB Chemicals…

Global Briefs: Viatris, Sanofi, Lilly, Pfizer & More 
By

By
A roundup of news from Viatris/Biocon, Sanofi/ViceBio, Eli Lilly and Company/Adverum Biotechnologies and Pfizer/YaoPharma. Highlights below.   General * Biocon To Buy Out Viatris in Biocon Biologics for $815 M  M&A News * Sanofi Completes Acquisition of Vicebio in $1.6-Bn Deal*…

AstraZeneca To Invest $2 Bn in US Biologics & Clinical-Scale Mfg 
By

By
AstraZeneca has announced plans to invest $2 billion to expand its manufacturing footprint in Maryland. This includes an expansion of its flagship biologics manufacturing facility in Frederick and construction of a new facility in…